A Phase 1 Clinical Trial of CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Exocrine Pancreatic Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 09 Dec 2019
Price : $35 *
At a glance
- Drugs CEND-1 (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- Sponsors DrugCendR
- 04 Dec 2019 Planned End Date changed from 30 Dec 2019 to 31 Dec 2020.
- 04 Dec 2019 Status changed from recruiting to active, no longer recruiting.
- 31 Jan 2019 Early data from the study, presented in a DrugCendR media release.